Update on treatment and prevention guidelines for HIV-related tuberculosis.

Research output: Contribution to journalArticle

Abstract

A report published in October 1998 contains guidelines on managing HIV-related tuberculosis based on recommendations by two panels convened by the Centers for Disease Control and Prevention (CDC). The major topics include treatment options for active tuberculosis, drug interactions between rifamycins and antiretroviral drugs, and preventive therapy. HIV-infected patients should receive prompt treatment with a multidrug regimen, and should be evaluated for antiretroviral therapy (HAART). A decision tree of recommended management strategies is given. All HIV-positive patients with a positive tuberculin skin test should receive directly observed therapy (DOT). Drug interactions between rifamycins and protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) pose serious patient management problems. Dosing of HAART should be modified according to rifabutin levels.

Original languageEnglish (US)
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Volume11
Issue number3
StatePublished - 1999
Externally publishedYes

Fingerprint

Rifamycins
Tuberculosis
Highly Active Antiretroviral Therapy
HIV
Guidelines
Drug Interactions
Directly Observed Therapy
Rifabutin
Decision Trees
Tuberculin Test
Reverse Transcriptase Inhibitors
Centers for Disease Control and Prevention (U.S.)
Skin Tests
Protease Inhibitors
Therapeutics
Drug Therapy

Cite this

@article{fb000860b0484fb296a78821c86a8ecd,
title = "Update on treatment and prevention guidelines for HIV-related tuberculosis.",
abstract = "A report published in October 1998 contains guidelines on managing HIV-related tuberculosis based on recommendations by two panels convened by the Centers for Disease Control and Prevention (CDC). The major topics include treatment options for active tuberculosis, drug interactions between rifamycins and antiretroviral drugs, and preventive therapy. HIV-infected patients should receive prompt treatment with a multidrug regimen, and should be evaluated for antiretroviral therapy (HAART). A decision tree of recommended management strategies is given. All HIV-positive patients with a positive tuberculin skin test should receive directly observed therapy (DOT). Drug interactions between rifamycins and protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) pose serious patient management problems. Dosing of HAART should be modified according to rifabutin levels.",
author = "Chaisson, {Richard E}",
year = "1999",
language = "English (US)",
volume = "11",
journal = "The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service",
issn = "1551-8396",
publisher = "Johns Hopkins University Press",
number = "3",

}

TY - JOUR

T1 - Update on treatment and prevention guidelines for HIV-related tuberculosis.

AU - Chaisson, Richard E

PY - 1999

Y1 - 1999

N2 - A report published in October 1998 contains guidelines on managing HIV-related tuberculosis based on recommendations by two panels convened by the Centers for Disease Control and Prevention (CDC). The major topics include treatment options for active tuberculosis, drug interactions between rifamycins and antiretroviral drugs, and preventive therapy. HIV-infected patients should receive prompt treatment with a multidrug regimen, and should be evaluated for antiretroviral therapy (HAART). A decision tree of recommended management strategies is given. All HIV-positive patients with a positive tuberculin skin test should receive directly observed therapy (DOT). Drug interactions between rifamycins and protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) pose serious patient management problems. Dosing of HAART should be modified according to rifabutin levels.

AB - A report published in October 1998 contains guidelines on managing HIV-related tuberculosis based on recommendations by two panels convened by the Centers for Disease Control and Prevention (CDC). The major topics include treatment options for active tuberculosis, drug interactions between rifamycins and antiretroviral drugs, and preventive therapy. HIV-infected patients should receive prompt treatment with a multidrug regimen, and should be evaluated for antiretroviral therapy (HAART). A decision tree of recommended management strategies is given. All HIV-positive patients with a positive tuberculin skin test should receive directly observed therapy (DOT). Drug interactions between rifamycins and protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) pose serious patient management problems. Dosing of HAART should be modified according to rifabutin levels.

UR - http://www.scopus.com/inward/record.url?scp=0033123103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033123103&partnerID=8YFLogxK

M3 - Article

C2 - 11367371

AN - SCOPUS:0033123103

VL - 11

JO - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

JF - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

SN - 1551-8396

IS - 3

ER -